Kim Cobleigh Drapkin, CPA
Board Member
Kim Cobleigh Drapkin, CPA, is a seasoned financial leader with over 30 years of experience guiding private and publicly traded biotechnology and pharmaceutical companies through strategic growth, financial planning, capital raises, and transformative transactions. Most recently, she served as Chief Executive Officer of Graphite Bio. Prior to that, she was Chief Financial Officer at Jounce Therapeutics, where she played a pivotal role in establishing the company’s financial infrastructure. She also founded and led a consulting firm, serving as interim CFO for multiple early-stage biotech companies within the Third Rock Ventures portfolio, including Jounce Therapeutics. Earlier in her career, Ms. Drapkin was CFO at EPIX Pharmaceuticals and held increasingly senior financial roles at Millennium Pharmaceuticals. She began her career in the technology and life sciences practice at PricewaterhouseCoopers LLP. Ms. Drapkin currently serves on the Boards of Acumen Pharmaceuticals (Nasdaq: ABOS), Imugene (ASX: IMU), LENZ (Nasdaq: LENZ), and Lucy Therapeutics, chairing the audit committees at Acumen and Imugene. She previously served as a board member of Kineta, Proteostasis, and Yumanity Therapeutics. Ms. Drapkin holds a B.S. in Accounting from Babson College.